Bevacizumab (pronounced /bev-a-Sizz-uh-mab/, trade name Avastin, Genentech/Roche) is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels.Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). VEGF-A is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer.
| Attributes | Values |
|---|---|
| rdfs:comment |
|
| ATC prefix |
|
| ATC suffix |
|
| Bioavailability |
|
| CAS number |
|
| DrugBank |
|
| FDA UNII code |
|
| is product of |